טוען...
PEGylation enables subcutaneously administered nanoparticles to induce antigen-specific immune tolerance
The development of nanomaterials to induce antigen-specific immune tolerance has shown promise for treating autoimmune diseases. While PEGylation has been widely used to reduce host immune responses to nanomaterials, its tolerogenic potential has not been reported. Here, we report for the first time...
שמור ב:
| הוצא לאור ב: | J Control Release |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7968989/ https://ncbi.nlm.nih.gov/pubmed/33450320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2021.01.013 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|